ARTICLE | Clinical News
Xarelto rivaroxaban regulatory update
July 4, 2011 7:00 AM UTC
FDA approved an NDA from Johnson & Johnson for Xarelto rivaroxaban to prevent deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients undergoing knee or hip replacement surgery. J&J will begin shipping Xarelto within the next few days. The wholesale acquisition cost for the once-daily direct Factor Xa inhibitor is $6.75 per tablet. ...